Asieris Enters an Exclusive Licensing Agreement with Theramex for CEVIRA

Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative therapies for the treatment of genitourinary tumors and women’s health, and Theramex, a global specialty pharmaceutical company dedicated to women and their health, today announced that they have entered into an exclusive licensing agreement for CEVIRA^® (APL-1702) covering all countries in Europe, as well as Australia, New Zealand and Turkey. Asieris retains the rights for the rest of the world.

Asieris’ media release states that the licensing agreement with Theramex for Cevira is subject to certain conditions, advancing the global development and commercialization of a first-in-class non-surgical treatment for cervical precancerous lesions in Europe.

Cevira (APL-1702) is a photodynamic drug-device combination product for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. In March 2026, Cevira had received approval from China’s National Medical Products Administration as a non-invasive therapy for cervical precancerous lesions.

Read Asieris’ full media release here: Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® (APL-1702) subject to certain conditions, Advancing the Global Development and Commercialization of a First-in-Class Non-Surgical Treatment for Cervical Precancerous Lesions in Europe - Asieris Pharmaceuticals